Physician profile
Adam Kilian
NPI 1497174015
$565,281.47
in general payments reported to CMS, 2019-2025
22 companies · $361K in 2025
The $361K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $136 · 2021: $16.45 · 2022: $224 · 2023: $2,234 · 2024: $158K · 2025: $361K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $381K · Travel and Lodging: $86K · Consulting Fee: $39K · Food and Beverage: $15K · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $380,548.00 |
| Travel and Lodging | $85,964.27 |
| Consulting Fee | $39,000.25 |
| Food and Beverage | $15,091.58 |
| Education | $214.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $307,799.41 | 2019-2025 | Tavneos, Uplizna, Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $99,950.34 | 2022-2025 | Saphnelo, Fasenra |
| Abbvie INC. | $52,413.52 | 2021-2025 | |
| Pfizer INC. | $43,863.24 | 2019-2025 | |
| Janssen Biotech, INC. | $34,423.48 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $14,662.29 | 2025 | |
| Novartis Pharmaceuticals Corporation | $9,008.05 | 2019-2024 | Cosentyx |
| Astrazeneca Uk Limited | $1,745.25 | 2025 | Fasenra |
| Glaxosmithkline, LLC. | $345.73 | 2019-2024 | |
| Lilly USA, LLC | $265.20 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $205.78 | 2019-2025 | Orencia |
| Janssen Scientific Affairs, LLC | $172.64 | 2024-2025 | Tremfya |
| Apellis Pharmaceuticals, INC. | $138.62 | 2025 | |
| Aurinia Pharma U.S., INC. | $126.75 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.46 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.24 | 2020 | |
| Fresenius Kabi USA, LLC | $20.70 | 2025 | |
| Bioventus LLC | $20.30 | 2020 | |
| Radius Health, INC. | $18.44 | 2019 | |
| Ucb, INC. | $17.97 | 2019 | |
| Merck Sharp & Dohme LLC | $16.10 | 2019 | |
| Horizon Therapeutics Plc | $15.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kilian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.